REGISTERED CHARITY NUMBER: 1143642 Report of the Trustees #Dd UDaudit¢d Fin4Dei*l Stattments for Iht Ye&r Ended 31 August 2025 for P$eudoNyKOrn• SMrvfv•r Harris Lacey and Swain Suite I The Riverside Building H¢551e East Yorkshre HU13 ODZ
Psevdomyxoma Survivor Contents of the Fin#neial Stalemellts for the Year Ended JI August 2025 Page Report Of the Trll$ttts Ind¢peDdeDt Eiamin¢r's Report Stternent ofFin¥D¢il A¢tfvltlt$ Balanct Shttt Notts to the Finan¢iAI Stateents 10 to 16
bom+ The support network for those affected by pseudomyxoma peritonei. appendix cancers and rare peritoneal malignancies Registere(t charity 1143642 PSEUDOMYXOMASURVIVOR-ANNUAL REPORTTO 31 AUGUST2025 The trustees present their reportwith the financial statements of the charityfor the year gnded 31 August 2025. The trustees have adopted the provisions of Accouniing and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standèrd applicable in the UK and Republic of Ireland IFRS 1021 (effective 1 January 20191. OUR OBJECTIVES. AIMS AND ACTIVITIES: Pseudomyxoma SuNivor's main objectives las set out in the Constitution) are= To relieve the sickness. mental and emotional distress of those suffering trom pseudomyxoma Pgritonei IPMPI. their families and Carers. To provide funds to support research into pseudomyxoma peritonei, its causes. trearment and cure and to publish the useful results of such research. To promote awareness of pseudomyxoma peritonei. Notice of bereavement: It Ss with deep sorrow that we announced the passing of our esteerned Trustee, Angela Brook in April 2025. Angela dfyvoted more than twelve years to the leadership and development of P5eudomyxoma SuNivor. and we were privileged to benefit Irom her unwavering commitment and setvice. As a palient livingwith pseudomyxoma peritDnei, Angela dedicated hertime and expertise to odvancingthe charity's mission. She played a pivotal rDle in building and maintaining our website. 8s well as establishing robust governance systems and procedures essential to the effective management of the charity. Angela's compassion and insight touched ¢ountless patients and their families. She provided invaluable support to patients and c8regivers, guiding them through unfamiliar and challenging circumst8nces wr(h empathy and understanding. Her Leg8cy is one of friendship, resilience. and profound dedicotion to the community she setvgd.
OURACHIEVEMENT AND PERFORMANCE: In orderto support our pationt$ and thgir c•rogiv8rs we have provided.. A website providing focussed advice. information and support. A private Facebookgroup, which ha5 over 1400 members from acro the world. Patients are b8sed in predominantly Engllsh-speaking countries with members wortdwide. Practical as well as emotional support to patients and families through our grant programme and h8V8 given financial support to 16 familios this year13 application5 were declined). A total pl £14,500 was paid. The ongoing provision of 8 Buddy Scheme to provide one-to-one support to patients and caregivers around the world. Access to a family flat in Manchester, to support the families of thos8 patients being tr8at8d 8tThe Christie. The flat is managed by the Christie Charitable Fund on our behalf. The flat contains personalised blankets and information about Pseudomyxoma Survivor. Fundingwas provided in previous years and will be done $0 again as required. Ward toiletiies to The Christie and Basingstoke. Support to patient days at both the Christie and Basingstoke hospit81s In orderto promote awargn088 of p8•udomyxom4 porlionel. Trustees have.. Attended the 14th International CongTess on Peritoneal Surt8ce Malignancies in Lyon, France. The conference was a joint meeting of the Peritone81 Surface Oncology Group International IPSOGII and the International Societyfor the Study ot Pleura and Peritoneum IISSPPI and dedicated to improvingthe treatment and survival of p8riion881 metastases. Attended various sessions hosted by National Volces. Findacure and data studies Attended Cancer52 meetings Promoted Rare Disease Day128th February 20251 Published weekly posts on oli social media channels reg8rding the dise8S0 Supported many competitors and volunteers, by providing merch8ndise for a wide variety of events Provided specialist leaflets forthe hospitals to hand out to patients. We have contributed funds to the following resgarch programmes during the year to 31 August 2025.. The team at the Peritoneal Malignancy Institute 81 Basingstoke & North Hampshire Hospitals NHS Foundalion Trust are undèrtaking a research programme to analyse patient data to craft a machine 188rning predictive modelfor recurrence and survival, to guide clinical decisions and treatment plans. We are Continuing to monitorthe Norwegian GNAS Vaccine Trial at Oslo University Qslo Un_Lve.r5lty GNAS r¢sevirchprogiamimc We are delighted to confirm this has now been approved for human patient trials and the first patient ha5 received their vaccine. We continue to provide pro-bono support of research trials and studies: Assistance with an application towards a dietary study in Australi8 etc.
Pseudomyxoma Survivor's purpose and its activititss contribute to the public benelit through activities to support these objectives. We are here lo help patients understand the treatment options. provide leaflets and online resources that they can trust. We representthe PMP community through links with other rare disease charities, by attending conferences and by supporting events organised to raise awareness ofthe disease. We take pride in the stewardship ol our donations. which we demonstrated through this yearwith our committed registration with the Fundraising Regulator. Pseudomyxoma Survivor has paid due regard to the Charity Commission's general guidance on public berielit when reviewing ils aims and objectives and in planning its future activities. Charitable actlvities: Pseudomyxoma is entirely reliant upon donations tor our income and due to ourvery generous supporters. we have received £124.369 in donations and other income. We are indebted to 811 of our fundraisers and theirfamilies and friends for their generosity- Our Facebook support group goes from strength to strength, and we have continued support tor the pseudomyxoma peritonei community on R8reConneet, 8 Eurordis initiative that provides a multi-lingual support platform for rare diseases and on the platform opgrated by Cancer Research. We have continued to develop a close working relationship with the teams at the Basingstoke and North HampshiTe Hospital and The Christie Hospital in Manchester. which allows us to better support patients, and identify research opportunities. Once again we were able to retain our status with the Great Non Profits organisation. FINANCIAL REVIEW Financlal position: We ale extrem&Ly pleased that we have total funds of £257.787 at the end of the fin8n¢ial year. With appropriate and controlled govèrnance procedures in place, the trustees Goniinue to be confident that gronts and awareness activities Can increase the value of the charityto the Community. PseudomyKoma Survivor's incom8 and expenditure is Kelatively small and consequently the charity does not have suflicient funds to invest in longer term investments such as stocks and shares. R8ser¥es poticy: ThrDugh prudence in our activities. we are now able to en$ureth8t we have a reserve in future years. We will do this through our plan which ensures the charity has feserves to cover our patient grant scheme, basic resources required to keep us 'in business, and to attend conlerences where we can represent the voice of the PMP community goingforward. for 24 monlhs. With appropriate and controlled governance proeedures in place. the trustees continue to bts confident that grants and awareness activities can incr8ase the value of the charity to the community. Duringthe yearto 31 August 2025. 12 months, expenditure eqv8ted to £31,931. plus the expenditure on research of £36.000 and family grants of £14,500, tot8lling £82.431. Whereas reserves at the pèriod end totalled £257,787 and reserves excluding designated funds totalled £121,287. We have designated expenditure as at the year ended 31 August 2025 of £136,50012024-. £79,0981 which will be spent in accordance with our ch8rit8ble objectives. aims and aetiwlies which are detailed in the Trusiee Report. All oppc>rtunities will be scrutinised in accordance with our due diligence procedures before any expenditure is committed.
Future plan8: With very grateful thanks to our very generous donors, we have plans in place to fi'nancially support the foiiowin8 initiatives during the financialyear 202512026.. The ongoing provision of family and caiegivers accommodation at the Christi& Hospital in Manchester. We will continue to promote the Family Grants to give financial support where appropriate. We will continue to monitor th& team at th8 B8singstoke Hospital on the Tesearch programme which aims to analyse patient data to craft a m8¢hine learning predictive model for recurrence and survival, to guide clinical decisions and treatment plans. The team at the Christie Hospital in Manchester are in very early stage discussions with us regBrding a new research project for which funding of £100,000 May be requested. We will have discussions with the Christie Hospital in Manchester to continue to monitor and suppon the prehabilitation study. We will kggp in touch with ail of our patients and caregivers especially when we know that they are going through stressful srtuations. We will continue to closely monitorthe NonMegiBn GNAS research programme, which has now been approvBd and ent8r8d inio patienttrials.
P$¢udom0M1 Survivor Rep)rt of the Tru$tces for the YtAr Ended JI Augusl Z025 STRucfuRE, GOVERNANCE AIYD MANAGEMENT CoverniDg documtni The charity is controlled by L15 governing document, a d¢d of irusl constitutes an urtittcorporaied charity. Rtcruitmtnt lppointmtllt of new trustets Trustees are appointed by th¢ ¢xisting trustee5. We are delighted thai Madeleine Lomas has bttn appointed a Trustee with etyect 23 Jun¢ 2025. Oryalli$itloA*l structsre In addition to the Trustees we havc a group of voluntccrs who activcly undcrtake the day to day administration of the FaCe0k group and a fvrthcr 60 who volunicer &$ Buddys on the Buddy schetne. Our people Pseudomyxoma Survivor relies entirely on the d¢dication of volunteers lo deliveT and manage the activities of our charity, We are fortwlaie to hav¢ fJv¢ aetive Trglet5. each bringing a wealth of 5kn11s and ¢XFeri¢nre that will help us grow and thrive in th¢ y¢ar5 ahead. Th¢iT COll)ffiitin¢nt and generosily in giving their time to SUPr( th¢ Charity is invaluablc. W¢ would also like to exiend our heart11 thanks 10 all of our volunieers this firla1 year, particulaTly Ihtyse who moderat¢ the Patient group and manage the buddie5 sch¢m¢. A special acknowledent goes io Mark Pon5ford. who l¢d gn online patieni discussion torum every week since 2018. This retnarkable level of commitmeni 10 th¢ ihariiy and io fellow patients is deeply 3ppr¢riated. REFERENCE AND ADMINISTRATIVE DETAIts Registtrtd Charity number 1143642 Principal ¥ddre$$ Appleir¢¢ House Mill Lane. Ellerlo York Y042 4PA TThstetS Mrs S Oliver Mr T Brill Mrs C Fletcher Mrs A C Salisbury Mrs A B Brook Ideceased 2.4.251 Ms M C Lorllas {appoinied 23.6.251 llldependent Ex4mither Harris Lacey and Swain Suite I The Riverside Building He551¢ East Yorkshire HU13 ODZ Page 5
Pstydomyxoma Surviv(pr Report of the Tru5tee5 for thé Yexr Ended 31 Augllst 2025 Approv¢d by order of the board of truseS on.....30 December 2025 and signed on its behalf by- tr-JJ Mrs A C Salisbwy- Ttuske Page 6
llldeptttdent Eximtner's Report to the Trustees of Pseudomyxom¥ Survivor Ihd*pendeht t%#iller'S report to tht trustees of Pseudrlmyxoma Survivor l Tey)rt to the charity IfLislees on my examination ot. the accounts of P5¢udOinorna Surviv¢r (the T1) for the ar etKled 31 AllE$t 2025. Respon5ibilitie5 and b¥si5 of report As the charity trLJsiees of the TrLLSt you are resporsible for the preparation of the ac¢ounts in arth)rd#n¢¢ with the requirements of th¢ Charitl¢5 AGt 201 I Ilhe Aci'l. J repon in respect of rtly exam1rtIOn tsf the Trust's accounts ¢arTied out under Section 145 ofihe Aci and in carrying o my examination I have followed all applicabl¢ Direction5 given by ihe Charity Cotnmi55ion under Section 14515Xbl of the Act. JndepeJdent exarniner's statsment I have completed my examittaiion. J Lonfimi Ih8t no material matters hav¢ come io my attention in conn¢clion with th¢ examinaiion gi¥in8 me cause to believe that in any material respect.. accounting records were not kept in respect of th¢ Trust as requir¢d by Section 130 of the Aci., or tk accDunts do nDt accord with thos¢ rccords," or the accounts do not cornply with th¢ applicable requiretnents conreming the totm and tonteni of accounis set out ir) the Charitie5 IAcLounts atkl Reports) Re%atiOnS 2008 other than any req112r¢ment that the accounts give true and fair vi¢w which is noi a matter considered as part of an indyndenl exaTnI[1i0n. I have no concerns and have corne across no oth¢T inatters in conn¢¢tion with the examination to which attention should be drawn in ihis rewirt in order to enable a proper understanding of the acwunts to bc TeJchcd. Laur8 Drew HaTris La¢¢y ond Swain Suit¢ I The RiveTside Building Hessle EA$t YoTkshire HU13 ODZ Dai¢.. Page 7
PstudomyXo1 Survlvor Sigtem¢nt of Finanf IAI Aitivitie5 for the YtAr Endtd 31 August 2015 2025 Total funds 2024 Total fid5 Unresiricied nds Restricted funds Noies INCOME AND ENDOWMENTS FROM Donations and legacies 124).IKII 1,895 121,896 64.216 Investment income 2,473 2,473 Total 122.474 1,89> 124.369 64,216 EXPENDITURE ON Raising fijnds 9,648 9.648 9,293 Chrltabl #ttlvltlts Charitable aitivit¢5 Grant making Support Costs 19,883 14,655 1.920 19,883 50,980 1.920 12.621 53,513 .830 36,325 Tot#1 46,106 36,325 82,431 77.257 NET INCOMFJIEXPENDrrvRE) 76.368 128,9551 134.4301 28,955 41,938 113,041) TrAtssfers bttwttn funds 12 Net movtmttht itt funds J17,4l3 li,47il 41,938 113.041} RECONCILIATION OF FUNDS Totsl ndS brought forward 210,374 5.475 215.849 228.890 TOTAL FUNDS CARRIED FORWARI) 257,787 257.787 215.849 The notes form part of these financial siaicmcnis Page 8
P5eudomyxotn4 Survivor ¥I¥nce Sht 31 August 2025 2025 Total funds 2024 Total fvnds Unre$tiieied funds ResiTiclcd fvnds Notes CURRENT ASSETS Debtors Cash at bank 10 1.172 ?58.535 1.172 258,535 1,993 217,382 259.707 259,707 219,375 CREDITORS Arnounis fallin8 due within one year (1,9201 11,9201 13,5261 NET CURRENT ASSETS 257,787 257.787 215,849 TOTAL Assrfs LESS CURRENT LIABILITIES 257.787 257,787 215.849 NET ASSETS 257,787 257,787 215,849 FUNDS 12 Unrestricted funds Re5tricl¢d funds 257,787 210,374 5.475 TOTAL FUNDS 257,787 215.849 The flnancial staiemenis were approved by the Board ot TTUSlttS and authoriscd for issue ..30 Dcc¢mkr 2025.... and w¢r¢ signed on ils behalf by.. on Fr-A.J._ Mrs A C Salisbury- TIiL%t¢e The rrf)les form part of these fJnancia] giatcmcnts Page 9
P$eudomyxotth Sllrvfvor Notes to the Financial Staternents for the YtXT Ended 31 August 2025 ACCOUNTING POLICIES Blsis of prepxTirtg the fillxneil statements The tinanrial 5t>ternenlS of the charity. which 1$ a public benefit emiity und¢T FRS 102. have been prepared in ac¢ordanLe wilh the Chariiies SORP IFRS 1021 'Accounting and ReFK>rtlDg by Cknril2e$.. Stsiern¢nt of Recomjnended Practice applicable to LharitlLS prcparing IhciT aecounls in accordance with the Financial Reporting Standard applicable In Ihc UK and Rcpublic of Ireland IFRS 1021 (effective l January 20191.. Financial Reporting Standard 102 'The Financial RertIng Standard applicable in the UK and Republic of Ireland. and the Charities ALI 2011. The financial siatements hav¢ been pr¢par¢d un(kr the tlislorical cost convention. ID¢ome Income r¢ceived for seryites provided is accounted for on an accruals basis. Cash donalivns, gilts and legacies are included in full in t]ie income and expenditure account tILey are receiv¢d. Any sirIcant non donation5 3r¢ included in the income and expendiiurc account at the Iiustees, cstitnai¢ of their rnarket vttlue when received. The value of voluniary klp is not included in the accoun13. Grhnts and other fundin8 of a revenue naiure are deferred and relea5¢d lo the inwme and exp¢nditur¢ account over th¢ period to which they relate. Bank interest is includd in the incotne and expertditure account on an accruals b&8iS. Expenditure Liabililieb are Tetognised as expenditure as 500n a5 Ihere is a legaj or con51rvclive obligation cgmmitting the charity to Ihar ¢xp¢nditure, it is probabl¢ that a transfer of cconotnic bcn¢tiis will be requirtd in senlemeni and Ihc amount of Ihc obligaiion can b¢ rn¢asured reliably. ExptndiiuTe is a¢¢ounted for on art a¢eruals basis and h en cla55ifi¢d und¢r headirw that Yggregaie all cosi related 10 ihe category. Where costs canNt be dir¢cily atlributcd to particular headings they have be aJlocat¢d to activities on a basis consi8rcnl with the use of resource5. Grknis offered subjeet to COtLdiiions which havt noi b¢¢n mer ai the end date are noted a5 a cornmitm¢nt but rM)t accrued as exF¢nditure. Taxation Thc chlty L5 ¢x¢ri)pt frotn on its charitable aciiviiies. Fu4d accountin¥ UnrestFict¢d lunds can b¢ used in accordance wilh the chJritabl¢ objective$ at the discretion of the Iruslees. Restricied tunds can only be uKd for parUcul?r restricted purposes wiihin the objecis o(Ihe charity. Resiriction5 rise when sp¢cifi¢d by the donor OT when lun(L% are iaised for pariicular restricted purposes. Further planation of the tL4iure and putpose of each filnd is incILed in ihe tLOi¢S to th¢ finaticial 5tal¢m¢tLts. Estimates and judgemtnts Esiirnat¢s a[ jud8etnenlS ate continually evaluated and are based on historical expcriencc and other factors, including CXPCClalions of future cvents that are b¢li¢v¢d to b¢ r¢asonable under Ihe cir¢umsiances. Although thes¢ estimates are based On the DirettOT$' besi knowledge of the amouni. events or a¢t10t actual T¢suIts ultimdlely dirrer from ¢le esiinutts. The Dir¢ctor5 do not consider there to bc any maierial estimates and judgements. Pag¢ 10 Continued...
P5eudomyxomi STAryivor Note5 to the Fithxtt¢ial Stxttme#t$- tontinued f4Jr the Year Ended JI August 2025 ACCOUNTING POLICILS- tontittued Fin*ncial iDStruments Thc compan>. only ha5 financial assets and financial liabilities of a kind that qUlfy as basic fLn8ncial instruments. Ba55c financial in5trutnetLlS, including trade and other debtors and ¢dItOrs. are initially recognis¢d ai IransaLiion valu¢ and subs¢qu¢ntly m¢a5ured at their 5eiilern¢nt value. INVFSTMENT INCOME 2025 2024 Deposit account interest 2.473 RAISING FUNDS Raising donations xnd leiacies 2025 2024 j81 Giying Costs of generating fillid5 2,173 7.475 1,325 7,968 9,648 9,293 CHARABLE AcfivITIES COSTS Grani fundin8 of Support COSt51see note 6) Direct Costs Isc¢ noi¢ 51 Totals Charitsble activites Grant making Support costs 19.883 19,883 50.980 1,920 50.980 .920 19.883 50.980 1,920 72,783 GK4NTS PAYABLE 2025 2024 Grant nknn8 50,980 53,513 The li)1 grants paid to inslituiions during the year %v4s as follows.. 2025 2024 Granis given 36.QO 46,000 A grani totallin8 £36.000 wa8 awarded to The PeTitQDeal Malignancy Insiiiuie ai Basingsioke Hospiial towards r¢5¢arch to an#lys¢ patient data to craft a Machine Learning pr¢dicliv¢ fflod¢l for recutrence and survival. to guide ¢liniLal decisions and ir¢aimeni plan5. P8g¢ 11 Continued...
Pseudomyxoma Survivor Note5 to the Fin4Dcial StatemEntS- Cotttithtted lor the Year EDdtd 31 Augu512025 SUPPORT COSTS Gov¢rnance COSts Support costs 1,920 Support costs, included in the above. are as follow5.' 2025 Support costs 2024 Total activities Independent cxaminalion 1.920 1,830 TRUSTEES, REMUNERATION AND BENEFITS Ther¢ was trtte$. remunerattotj iotalling £9,000 12024 - £8,820) bui no other benefits for th¢ year ¢rKied 31 August 2025 or oiher benefiis for tlie year ¢nd¢d 31 Augvst 2024. The remuncraiion received by Mrs S Oliver for their Tole as the Ch&rity's administraior, after much constdevdtion by the board as to how fjll this role. This was recordd in the Charity's ly)ard tneeting rninules. Tru5te¢s' txpensts There were no 31 August 2024. ITltslttS' expenses paid for the year ended 31 August 202) nor for th¢ year ended STAFF COSTS There w¢r¢ JKk siaff Costs f(PT th¢ year ended 31 August 2025 nor for the year ended 31 August 2024. The av¢rug¢ numkr of employee5 durin% the year NIL12024- NIL). No employees received emoluments in exeess of £60,000. COMPAIL4TIVES FOR THE STATEMENT OF FINANCIAL ACTlVtriES UnrestTiCted nds Restricted funds Toial turyJ5 INCOME AND ENDOWMENTS FROM Dvnalions legacies 58,741 5,475 64,216 EXPENDITURE ON Raising fvrKi8 9,293 9,293 Charitable *¢dvlik$ Charitable aciivilcs Grant makang Stspp)rt costs 12,621 22.513 1,830 12,621 53.513 1,830 31.000 Total 46,257 31,000 77.257 NET INCOMEIIEXPENDITUREI 12,484 (25,525) 113,0411 Page 12 oniinued...
P5eudomy¥oma SwrvivoT Notts to the FinaAcial St3ttments- tontlAued for th¢ Year Ended 31 August 2025 COMPARATIVES FOR THE &fATEMENT OF FINANCIAL ACTIVITIES- continu¢d Unresiricied fund5 Restricted fvnds Total fund5 Tr*kn$ftrs bttwttn funds 131.0001 31,000 Net movernent in funds 5,475 {13.041} RECONCILIATION OF FUNDS Total funds broughi forward 228.890 228,890 TOTAL FUNDS CARIUED FORWARD 210,374 5.475 215.849 10. DEBTORS.. AMOUIYTS FALLING DUE WITHIN ONE YEAR 2025 2024 Oiher debiors Prepayments and accrued income ,025 147 1,846 147 1.172 1,993 ii. cREDORS. Amoupffs FALLINC DUE WITHIN ONE YEAR 2025 2024 Trade ctediiors Other crediiors 1,696 1.830 1,920 1,920 3.526 12. MOVEMENT IN Fuf+4DS Nei tnovejnenl in funds Transfers between fijnds At 1.9.24 31.8.25 Unre5trieted funds Gtncral fund Designated fund 131,276 79,098 76,368 186,3571 57,402 121,287 136.500 210,374 76,368 128,9551 257,787 Re5trirted funds Research fund 5,475 134,4301 28,955 TOTAL FUNDS 215.849 41,938 257.787 Page 13 conliDued..
Pseudomyxoma Survhvor Notes to the FinHn¢ial Staternent5- continued for the Year Ended 31 August 2025 12. MOVEMENT IIY FUNDS- continued Ncl movement in funds, included in the aknv¢ are as follows.. Incotning resources R¢50urce5 expended Movern¢tLt in fvnds Unrestricted fuTrd5 Geneial fund 122.474 146,1061 76,368 Restricted funds Research fund Family grants 1,570 325 (36.0001 {34,4301 .895 136.325} 134,4301 TOTAL FUNDS 124.369 {82,4311 41,938 Comparatives for Jnovement in fulbds Transfer5 b¢tween ovemeDI in funds At 31.8.24 Ai 1.9.?3 Unr¢strict¢d funds GeneTal fund Iksign&ted fund 111.390 117,500 12,484 7,402 138,4021 131,276 79.098 228,890 12.484 131,000) 210,374 Restricted funds Research fund 125,5251 31,000 5,475 TOTAL FUNDS 228,890 113,0411 215,849 Comparative n¢t Jnovement in funds. included in the above are as follows.. Incoming resources RegouTttS expended Movetllent in ndS Unrestricted fuxd8 General fund 58.741 (46,2571 12,484 Restricted funds R¢s¢ar¢h fvnd 5,475 131,000) 125,5251 TOTAL FUNDS 64.?16 177.2571 Ili.0411 Page 14 continued...
Pseudomyxoma su1or Notts to tht Finan¢i*l StAtementS- ¢Olltittued for tht Year Ended 31 August 2025 12. MOVEMEfff IN FUNDS- tootinutd A current year 12 Monti and prior year 12 months wmbined position is &$ follows.. Nei movement in fun& Trnnsfers between tiind5 At 1.9.23 31.8.25 UnT¢5tricted fund$ General fund Designated fund 111.390 117,500 88,852 178,9551 19.000 121,287 136.500 228,890 88.852 159.9551 257,787 Rcstrttttd funds Research fvnd 159.9551 59,955 TOTAL FUNDS 228,890 28,897 257.787 A current year 12 months and prior year 12 Tnonths CobIned Det mQV¢Tnent in fvrtds, included in thc ab)vc are as follows: Jncoming resources ReSQUT¢¢5 expended Movetnent in funds Unrestricted fuuds General fund 181,215 (92.3631 88,852 Restrirted furtds Research fund Ftmily grartts 7,045 325 167.000) 13251 159,9551 7,370 167.3251 159,9551 TixfAL FUNDS 188.585 1159,688} 28,897 Re5trict¢d fvnd5 r¢late the provision of Ttst2rch funding. Transftrj bttwetn fuids Fund transfers during the y¢aT relate to th¢ tTattsfer5 of previously dcsi8Aated tiinds to cover actual spending in the year. The desi8rta(cd fund relates 10 monies ser aside for committed future spending. Page 15 coijtinu¢d...
P5tudomyxoma Survivor Note5 to the FiDiIDcil St*tethents- contiNutd for the Ytar Ended JI August 2025 13. RELATED PARTY DISCLOSURES There w¢r¢ no related party transactions for the year ended 31 Augusi 2025. Page 16